Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Pediatric haematopoiesis and related malignancies.

Jin M, Xu S, An Q.

Oncol Lett. 2017 Jul;14(1):10-14. doi: 10.3892/ol.2017.6106. Epub 2017 Apr 28.

2.

Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.

Lee JW, Cho B.

Korean J Pediatr. 2017 May;60(5):129-137. doi: 10.3345/kjp.2017.60.5.129. Epub 2017 May 31. Review.

3.

The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia.

Gossai NP, Gordon PM.

Front Pediatr. 2017 Apr 26;5:90. doi: 10.3389/fped.2017.00090. eCollection 2017. Review.

4.

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia.

Wei G, Ding L, Wang J, Hu Y, Huang H.

Exp Hematol Oncol. 2017 Apr 14;6:10. doi: 10.1186/s40164-017-0070-9. eCollection 2017. Review.

5.

A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).

Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, Blaney SM.

Br J Haematol. 2017 May;177(3):467-474. doi: 10.1111/bjh.14569. Epub 2017 Mar 14.

PMID:
28295182
6.

The genetics and molecular biology of T-ALL.

Girardi T, Vicente C, Cools J, De Keersmaecker K.

Blood. 2017 Mar 2;129(9):1113-1123. doi: 10.1182/blood-2016-10-706465. Epub 2017 Jan 23. Review.

7.

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen IM, Ryan T, Vincent TL, Willman CL, Perl AE, Hunger SP, Loh ML, Carroll M, Grupp SA.

Blood. 2017 Jan 12;129(2):177-187. doi: 10.1182/blood-2016-05-707653. Epub 2016 Oct 24.

PMID:
27777238
8.

T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.

Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T.

Oncotarget. 2016 Nov 22;7(47):76902-76919. doi: 10.18632/oncotarget.12357.

9.

Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia.

Dobrovinskaya O, Valencia-Cruz G, Castro-Sánchez L, Bonales-Alatorre EO, Liñan-Rico L, Pottosin I.

Front Pharmacol. 2016 Aug 31;7:290. doi: 10.3389/fphar.2016.00290. eCollection 2016.

10.

Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.

Yadav BD, Samuels AL, Wells JE, Sutton R, Venn NC, Bendak K, Anderson D, Marshall GM, Cole CH, Beesley AH, Kees UR, Lock RB.

Oncotarget. 2016 Sep 13;7(37):58728-42. doi: 10.18632/oncotarget.11233.

11.

Extramedullary Relapse of Acute Myeloid and Lymphoid Leukemia in Children: A Retrospective Analysis.

Young Kim J, Ah Im S, Hyun Lee J, Wook Lee J, Gyun Chung N, Cho B.

Iran J Pediatr. 2016 May 28;26(3):e1711. doi: 10.5812/ijp.1711. eCollection 2016 Jun.

12.

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.

Geyer MB, Brentjens RJ.

Cytotherapy. 2016 Nov;18(11):1393-1409. doi: 10.1016/j.jcyt.2016.07.003. Epub 2016 Aug 31. Review.

PMID:
27592405
13.

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, Billups CA, Erickson SW, Guo Y, Houghton PJ, Smith MA, Carol H, Roberts AW, Huang DC, Lock RB.

Blood. 2016 Sep 8;128(10):1382-95. doi: 10.1182/blood-2016-03-707414. Epub 2016 Jun 24.

PMID:
27343252
14.

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Cramer SD, Aplan PD, Durum SK.

Blood. 2016 Jul 28;128(4):473-8. doi: 10.1182/blood-2016-03-679209. Epub 2016 Jun 6. Review.

PMID:
27268088
15.

BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.

Slone WL, Moses BS, Hare I, Evans R, Piktel D, Gibson LF.

Oncotarget. 2016 Apr 26;7(17):23439-53. doi: 10.18632/oncotarget.8273.

16.

Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Maus MV, Levine BL.

Oncologist. 2016 May;21(5):608-17. doi: 10.1634/theoncologist.2015-0421. Epub 2016 Mar 23. Review.

17.

Modeling Chemotherapy Resistant Leukemia In Vitro.

Slone WL, Moses BS, Evans R, Piktel D, Martin KH, Petros W, Craig M, Gibson LF.

J Vis Exp. 2016 Feb 9;(108):e53645. doi: 10.3791/53645.

18.

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.

An N, Tao Z, Li S, Xing H, Tang K, Tian Z, Rao Q, Wang M, Wang J.

Oncotarget. 2016 Mar 1;7(9):10638-49. doi: 10.18632/oncotarget.7079.

19.

Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function.

Wang W, Zimmerman G, Huang X, Yu S, Myers J, Wang Y, Moreton S, Nthale J, Awadallah A, Beck R, Xin W, Wald D, Huang AY, Zhou L.

Cancer Res. 2016 Mar 15;76(6):1641-52. doi: 10.1158/0008-5472.CAN-15-2092. Epub 2016 Jan 22.

20.

The origin of relapse in pediatric T-cell acute lymphoblastic leukemia.

Vicente C, Cools J.

Haematologica. 2015 Nov;100(11):1373-5. doi: 10.3324/haematol.2015.136077. No abstract available.

Supplemental Content

Support Center